CD8A and neoplasm: Similarly, anti-IL-1β monoclonal antibody significantly enhanced the anti-tumor activity of anti-PD-1 antibodies in a preclinical model of PDAC, which was accompanied by increased infiltration of CD8 T cells into the tumor [25].